Trials / Conditions / FGFR2 Gene Mutation

FGFR2 Gene Mutation

10 registered clinical trials studyying FGFR2 Gene Mutation — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma NCT06728410	Mehmet Akce	Phase 2
Terminated	Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements NCT05565794	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Phase 2
Completed	Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma NCT04919642	TransThera Sciences (Nanjing), Inc.	Phase 2
Terminated	Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib NCT05052372	xCures	—
Completed	REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other NCT04526106	Elevar Therapeutics	Phase 1 / Phase 2
Unknown	Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations NCT04096417	Academic and Community Cancer Research United	Phase 2
Terminated	Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Transloca NCT03773302	QED Therapeutics, a BridgeBio company	Phase 3
Terminated	BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer NCT02706691	University of Chicago	Phase 2
Completed	Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous C NCT02965378	SWOG Cancer Research Network	Phase 2 / Phase 3
Terminated	A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma NCT02150967	QED Therapeutics, a BridgeBio company	Phase 2